1. Home
  2. COSM vs IMMP Comparison

COSM vs IMMP Comparison

Compare COSM & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cosmos Health Inc.

COSM

Cosmos Health Inc.

N/A

Current Price

$0.34

Market Cap

33.8M

Sector

Health Care

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

N/A

Current Price

$3.60

Market Cap

31.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
COSM
IMMP
Founded
2009
1987
Country
Greece
Australia
Employees
163
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.8M
31.5M
IPO Year
2009
2012

Fundamental Metrics

Financial Performance
Metric
COSM
IMMP
Price
$0.34
$3.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.6M
303.6K
Earning Date
11-16-2026
09-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 46.15
N/A
EPS
N/A
★ N/A
Revenue
★ $65,271,815.00
N/A
Revenue This Year
$23.79
N/A
Revenue Next Year
$58.42
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 19.93
N/A
52 Week Low
$0.16
$0.26
52 Week High
$1.26
$5.36

Technical Indicators

Market Signals
Indicator
COSM
IMMP
Relative Strength Index (RSI) 53.51 67.55
Support Level $0.27 $2.65
Resistance Level $0.35 $5.36
Average True Range (ATR) 0.05 0.22
MACD -0.01 0.11
Stochastic Oscillator 26.28 64.73

Price Performance

Historical Comparison
COSM
IMMP

About COSM Cosmos Health Inc.

Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: